Hizal, M. Et Al. 2022. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. FUTURE ONCOLOGY , vol.18 , 2573-2582.

Hizal, M., Bilgin, B., Paksoy, N., Kilickap, S., Atci, M. M., KAHRAMAN, S., ... KESKİNKILIÇ, M.(2022). Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. FUTURE ONCOLOGY , vol.18, 2573-2582.

Hizal, Mutlu Et Al. "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study," FUTURE ONCOLOGY , vol.18, 2573-2582, 2022

Hizal, Mutlu Et Al. "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study." FUTURE ONCOLOGY , vol.18, pp.2573-2582, 2022

Hizal, M. Et Al. (2022) . "Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study." FUTURE ONCOLOGY , vol.18, pp.2573-2582.

@article{article, author={Mutlu Hizal Et Al. }, title={Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study}, journal={FUTURE ONCOLOGY}, year=2022, pages={2573-2582} }